PHARMACY

NACDS Foundation seeks nominations for inaugural faculty scholars program

BY Antoinette Alexander

ALEXANDRIA, Va. — The National Association of Chain Drug Stores Foundation has launched a new program designed to annually educate assistant professors from U.S. schools and colleges of pharmacy about designing, implementing and publishing community pharmacy-based patient care research.

The NACDS Foundation Faculty Scholars Program will provide participants with advanced educational opportunities through in-person meetings, regular conference calls, individualized mentoring, Web-based lecture material and online discussion forums. Participating professors will obtain one-to-one coaching and support from experienced researchers at the University of Pittsburgh, and research grants to launch patient-centered care projects.

“The NACDS Foundation’s Faculty Scholars Program will help catalyze innovative research to explore community pharmacists’ role in impacting health outcomes and reducing costs through medication counseling and other health services,” stated NACDS Foundation president Kathleen Jaeger. “We are thrilled to foster research by young academics and provide them with a wealth of resources, including the opportunity to obtain expert advice from experienced researchers and engage in peer-to-peer review.”

The NACDS Foundation will accept five scholars for the inaugural 2012-2013 class. The first in-person meeting of the selected faculty members will be held during the NACDS Pharmacy & Technology Conference, to be held August 25 to 28 in Denver.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves first effervescent tablet for osteoporosis

BY Alaric DeArment

FREIENBACH, Switzerland — The Food and Drug Administration approved an effervescent tablet for treating osteoporosis.

EffRx Pharmaceuticals announced the FDA approval of Binosto (alendronate sodium), a strawberry-flavored tablet designed to dissolve in water that the company called the first treatment of its kind. The drug is designed to treat osteoporosis in menopausal women and increase bone mass in men with osteoporosis. EffRx expects to launch Binosto in third quarter 2012.

"Binosto is a breakthrough innovation for the treatment of osteoporosis, offering those patients that have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant-tasting and easy-to-swallow buffered solution," EffRx chairman and CEO Christer Rosen said.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves Bayer contraceptive for heavy menstrual bleeding

BY Alaric DeArment

WAYNE, N.J. — The Food and Drug Administration has approved a drug that the manufacturer called the first oral contraceptive that also treats heavy menstrual bleeding.

Bayer HealthCare Pharmaceuticals announced Wednesday the approval of Natazia (estradiol valerate and estradiol valerate and dienogest) tablets for heavy menstrual bleeding not caused by any conditions of the uterus. The drug was originally approved as an oral contraceptive in May 2010.

"Heavy menstrual bleeding is a common disorder reported by around 3 million women of reproductive age each year in the United States," Bayer HealthCare Pharmaceuticals VP and head of U.S. medical affairs Pamela Cyrus said. "As the first oral contraceptive treatment approved for heavy menstrual bleeding in women without organic pathology who choose an [oral contraceptive] for contraception, Natazia represents a new treatment approach for appropriate women with this medical condition."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES